Following a handful of deals for other biosimilar drugmakers, Pfizer decided to settle its Humira patent fight with AbbVie and agreed on a Nov. 20, 2023, U.S. launch date for its copy. More: AbbVie inks Humira patent deal No. 7,
read moreSanofi’s Lemtrada is already struggling in a tough multiple sclerosis field, and a new FDA safety warning isn’t going to help matters. Thursday, the agency put out a notice citing “rare but serious” cases of stroke and tears in the
read moreNovartis CEO Vas Narasimhan has repeatedly distanced himself from the dubious $1.2 million in payments the company made to President Donald Trump’s former personal lawyer Michael Cohen. What was it like for him hearing the news for the first time?
read moreIn September, Britain’s drug-cost watchdog National Institute for Health and Care Excellence (NICE) said Bristol-Myers Squibb’s PD-1 blocker Opdivo should not be covered for preventing relapses in melanoma patients after surgery. The company successfully appealed the decision—scoring an important win
read moreWith a critical shareholder vote looming next week, Takeda’s CFO says the company will consider selloffs of up to $10 billion to help fund its Shire buy, which is twice as much as had been reported previously. More: Takeda could
read moreNHS use of Bristol-Myers Squibb’s Opdivo to cut the risk of early stage skin cancer recurrence after surgery has now been approved by the National Institute for Health and Care Excellence More: NICE u-turn on Opdivo for skin cancer recurrence
read more© 1994 - 2021 B.M. Pharmaceuticals